ASCO 2022
Older adults with acute myeloid leukemia (AML) treated with hypomethylating agents (HMAs) have more time at home (TAH), ...
A study examined the clinical use of ultra-deep next-generation sequencing measurable residual disease (NGS-MRD) before ...
Researchers of a study sought to discern causes of treatment failure and early mortality in acute myeloid leukemia (AML) ...
Researchers assessed the incidence and clinical outcomes of non-ischemic or dilated cardiomyopathies in LVAD patients ...
In a meta-analysis presented at the 2022 American Society of Clinical Oncology Annual Meeting, researchers evaluated ...
According to research presented at the 2022 American Society of Clinical Oncology Annual Meeting, graft-versus-host ...
Hispanic patients had a significantly lower cumulative incidence of chronic graft-versus-host disease (GVHD) than ...
The first-in-human, phase I clinical trial of ADI-001, an allogeneic gamma delta chimeric antigen receptor (CAR) T-cell ...
A study presented at the 2022 American Society of Clinical Oncology Annual Meeting reported on results of a literature ...
Patients who received an allogeneic hematopoietic stem cell transplant (HSCT) from matched related donors (MRD) or ...
A study presented at the 2022 American Society of Clinical Oncology Annual Meeting found that an autologous CD7 chimeric ...
A retrospective study found that partially mismatched blood or marrow transplantation with post-transplantation ...
A study assessed autologous CD7 CAR-T therapy in refractory or relapsed r/r T-cell acute lymphoblastic leukemia/lymphoma ...
Researchers reported updated results from a phase I trial of donor-derived CD7 chimeric antigen receptor (CAR) T cells ...
Researchers assessed the Charlson comorbidity index (CCI) as a predictor of early mortality and overall survival (OS) in ...
Researchers from a study presented at the 2022 American Society of Clinical Oncology Annual Meeting identified ...
A recent analysis shows that shallow whole-genome sequencing (sWGS) is an accurate, convenient, and cost-effective ...
Researchers conducted a study to discern clinical predictors for the development of venous thromboembolism (VTE) in ...
The use of machine learning methods is a viable option for identifying patients with myelodysplastic syndrome (MDS), ...
Chronic myelomonocytic leukemia (CMML) is a heterogenous blood cancer which exhibits features similar to ...
Pyrotinib, a second-generation, irreversible anti-human epidermal growth factor receptor 2 (HER2) tyrosine kinase ...
Research presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting indicated that the following ...
The phase II MAINTAIN trial evaluated the efficacy of adding ribociclib to endocrine therapy in patients with hormone ...
Results of the DESTINY-Breast04 study, presented at the 2022 American Society of Clinical Oncology (ASCO) Annual ...
Rusfertide in conjunction with standard therapy is effective in managing polycythemia vera (PV) patients with poorly ...
Researchers assessed over 17,000 patient samples analyzed by targeted next generating sequencing (NGS) to discern the ...
Use of momelotinib (MMB) appears to be more effective than danazol (DAN) in symptomatic and anemic myelofibrosis (MF) ...
The recently FDA-approved ruxolitnib should be utilized more in the treatment of chronic steroid-refractory ...
Mutated Stromal Antigen 2 (mSTAG2) coding genes are more common in elderly men and patients with MDS.
Liquid biopsy (LB) serves as a robust tool for identifying genetic alterations in patients with myeloid neoplasms, ...
In an analysis of race/ethnicity outcomes in myeloproliferative neoplasms (MPN), data suggest that Non-Hispanic Whites ...
In this analysis, Francesco Passamonti and colleagues assessed 32 patients (median age, 69) who received NAV+RUX.
In a study presented at the 2022 American Society of Clinical Oncology Annual Meeting, researchers assessed two unique ...
According to a poster at the 2022 American Society of Clinical Oncology, the combination of the anti-CD47 monoclonal ...
Researchers, led by Amber Afzal, evaluated the effect of statins in patients with myelodysplastic syndromes (MDS) after ...
According to Jing Wang and collaborating researchers, the combination of sintilimab and decitabine is relative safe and ...
Researchers, led by Blade Langlais, sought to evaluate the heavily female-weighted gender disparity in online ...
Investigators, led by Naveen Pemmaraju, evaluated the toxicities and risk-adjusted safety of pacritinib, a novel ...
Haris Ali and collaborating researchers evaluated the combination of selinexor and ruxolitinib in patients with ...
In a presentation at the 2022 American Society of Clinical Oncology Annual Meeting, Prithviraj Bose and colleagues ...
According to Lucia Masarova and colleagues, the median therapy duration of ruxolitinib—a JAK inhibitor used in ...
According to a presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, momelotinib was ...
According to Ciro Roberto Rinaldi and collaborating researchers, CD47, but not calreticulin (CALR), was overexpressed on ...
According to Utsav Joshi and collaborating researchers, it is unclear whether patients with primary myelofibrosis (PMF) ...
Advertisement
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.